Provided by Tiger Trade Technology Pte. Ltd.

Eli Lilly

1,154.47
-20.1450-1.72%
Volume:557.08K
Turnover:642.90M
Market Cap:1.09T
PE:38.75
High:1,171.45
Open:1,168.04
Low:1,147.00
Close:1,174.61
52wk High:1,292.65
52wk Low:712.05
Shares:945.38M
Float Shares:939.00M
Volume Ratio:1.19
T/O Rate:0.06%
Dividend:6.69
Dividend Rate:0.58%
EPS(TTM):29.79
EPS(LYR):22.95
ROE:102.29%
ROA:20.36%
PB:32.22
PE(LYR):50.30

Loading ...

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
2 hours ago

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
2 hours ago

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
3 hours ago

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
3 hours ago

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
3 hours ago

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
3 hours ago

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
3 hours ago

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
3 hours ago

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
4 hours ago

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
4 hours ago

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
4 hours ago

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
4 hours ago

Pharma Industry Stares Down Biggest Patent Cliff in Decades

Dow Jones
·
Aug 29

Eli Lilly (LLY) Wins FDA Approval For Mounjaro Heart Risk Reduction

Simply Wall St.
·
Aug 29

Sector Update: Health Care Stocks Mixed Pre-Bell Friday

MT Newswires Live
·
Aug 28

FDA Approves Lilly's Mounjaro to Cut Cardiovascular Event Risk in High-Risk Type 2 Diabetes Adults

Reuters
·
Aug 28

FDA Approves Lilly's Mounjaro (Tirzepatide) to Reduce Cardiovascular Risk in Adults with Type 2 Diabetes

THOMSON REUTERS
·
Aug 28

Dow Jones Top Company Headlines at 11 PM ET: Judge Rules Trump Administration's Blacklisting of Anthropic was Unlawful | Nvidia ...

Dow Jones
·
Aug 28

Eli Lilly (LLY) Says Zepbound Cuts Healthcare Costs For Adults Over 55

Simply Wall St.
·
Aug 27

Eli Lilly & Co. Stock Slips 3.6%, Underperforms Peers

Dow Jones
·
Aug 27